Alnylam Grants Calando a License to Develop and Commercialize an RNAi Therapeutic Product

Target-Specific License for RNAi Intellectual Property Granted under Alnylam's InterfeRx(TM) Program

23-Aug-2006

Alnylam Pharmaceuticals, Inc. has granted Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation, an InterfeRx(TM) license to discover, develop, and commercialize an RNAi therapeutic utilizing a synthetic siRNA, together exclusively with Calando's proprietary delivery technology, that is directed towards a cancer target. As part of the agreement, Calando also has an option to acquire an InterfeRx license for a second target gene. Detailed financial terms were not disclosed, but include upfront, annual, and milestone payments, and royalties on sales of any products covered by the licensing agreement.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances